Last reviewed · How we verify
NCT07400198
Gait and Bone Health in SMA
trial in Spinal Muscular Atrophy Type 3 in 22 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Jacqueline Montes |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 22 |
| Start date | 5 March 2026 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2027 |
| Sites | 1 location across United States |
Conditions studied
- Spinal Muscular Atrophy Type 3 — all drugs for Spinal Muscular Atrophy Type 3 →
- Ambulatory Spinal Muscular Atrophy — all drugs for Ambulatory Spinal Muscular Atrophy →
Sponsor
Jacqueline Montes
Who can join
Adults 8 to 50, any sex, with Spinal Muscular Atrophy Type 3 or Ambulatory Spinal Muscular Atrophy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to understand how spatiotemporal and kinetic gait parameters are associated with bone health in pwSMA who are receiving DMT. We hypothesize that gait parameters are associated with BMD and can determine fracture risk in pwSMA. This is an observational study that involves one in-clinic visit (approximately 3 hours) with remote follow-up visits (approximately 15 minutes) every 3 months for 1 year to collect fracture and medical history. Each of the assessments included in this study are non-interventional and are not intended as a treatment nor are they at the level of standard of care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07400198
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Spinal Muscular Atrophy Type 3
Currently open trials in the same condition.
- NCT06839469 — Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders · recruiting
- NCT05626855 — Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Previous Trials of Apitegromab · Phase 3 · active not recruiting
- NCT03709784 — Spinraza in Adult Spinal Muscular Atrophy · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07400198 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jacqueline Montes
- Last refreshed: 18 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07400198.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing